Publications | Flatiron Health | Gastric cancer

Browse every publication tagged Gastric cancer

May 2026
Real-world biomarker testing rates, targeted therapy use, and clinical outcomes in patients with advanced gastric or GEJ cancer in the United States
- Precision medicine
- Gastric cancer
February 2023
Exposure to US cancer drugs with lack of confirmed benefit after US Food and Drug Administration accelerated approval
April 2022
Analysis of a real-world progression variable and related endpoints for patients with five different cancer types
June 2021
ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA)
- Clinical development
- Gastric cancer
March 2021
Adherence to and determinants of guideline-recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: insights from routine practice
- Gastric cancer
- Treatment and Testing patterns
May 2020
Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts)
- Clinical development
- Gastric cancer
June 2019
Organ dysfunction and clinical outcomes in patients treated with immune checkpoint inhibitors
April 2017
Chemotherapy use near end of life (EOL): measuring real world benchmarks